RARA and acute promyelocytic leukemia: A large body of evidence has shown that the transregulatory suppressor function of PML-RARA can be relieved by pharmacological levels of ATRA, leading to restoration of a normal granulocyte differentiation program and loss of clonal expansion capacity of APL-initiating cells (de The, 2018; Jiao et al., 2013) (Tan et al., 2020).